UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

International journal of cancer, 2007-01, Vol.120 (1), p.170-174

2007

Volltextzugriff (PDF)

Prostate cancer grading, time to go back to the future

BJU international, 2021-02, Vol.127 (2), p.165-168

2021

Volltextzugriff (PDF)

Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma

Cancer, 2004-04, Vol.100 (7), p.1397-1405

2004

Volltextzugriff (PDF)

Prostate Cancer Diffusion‐Weighted Magnetic Resonance Imaging: Does the Choice of Diffusion‐Weighting Level Matter?

Journal of magnetic resonance imaging, 2022-03, Vol.55 (3), p.842-853

2022

Volltextzugriff (PDF)

Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer

BJU international, 2024-08, Vol.134 (2), p.291-299

2024

Volltextzugriff (PDF)

Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial

BJU international, 2021-03, Vol.127 (3), p.361-368

2021

Volltextzugriff (PDF)

The dilemmas of prostate cancer screening

Medical journal of Australia, 2013-11, Vol.199 (9), p.583-584

2013

Volltextzugriff (PDF)

Risk of severe late toxicity after radiotherapy following radical prostatectomy – a nationwide study

BJU international, 2022-12, Vol.130 (6), p.799-808

2022

Volltextzugriff (PDF)

Lymph swelling after radical prostatectomy and pelvic lymph node dissection

BJU international, 2022-06, Vol.129 (6), p.695-698

2022

Volltextzugriff (PDF)

The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials

Cancer, 2018-03, Vol.124 (6), p.1197-1206

2018

Volltextzugriff (PDF)

Oncological and functional outcomes 1 year after radical prostatectomy for very‐low‐risk prostate cancer: results from the prospective LAPPRO trial

BJU international, 2016-08, Vol.118 (2), p.205-212

2016

Volltextzugriff (PDF)

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date

BJU international, 2018-05, Vol.121 (5), p.737-744

2018

Volltextzugriff (PDF)

Four-hundredfold overestimation of biopsy mortality

BJU international, 2013-03, Vol.111 (3), p.E16-E17

2013

Volltextzugriff (PDF)

Social constraints and psychological well-being after prostate cancer: A follow-up at 12 and 24months after surgery

Psycho-oncology (Chichester, England), 2018-02, Vol.27 (2), p.668

2018

Volltextzugriff (PDF)

Four‐hundredfold overestimation of biopsy mortality

BJU international, 2013-03, Vol.111 (3), p.E16-E17

2013

Volltextzugriff (PDF)

Population‐based, nationwide registration of prostatectomies in Sweden

Journal of surgical oncology, 2019-09, Vol.120 (4), p.803-812

2019

Volltextzugriff (PDF)

Social constraints and psychological well‐being after prostate cancer: A follow‐up at 12 and 24 months after surgery

Psycho-oncology (Chichester, England), 2018-02, Vol.27 (2), p.668-675

2018

Volltextzugriff (PDF)

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis

Cancer, 2016-11, Vol.122 (21), p.3386-3393

2016

Volltextzugriff (PDF)

The dilemmas of prostate cancer screening

Medical journal of Australia, 2013-06, Vol.198 (10), p.528-529

2013

Volltextzugriff (PDF)

Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen: Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden

Cancer, 2010-06, Vol.116 (11), p.2612-2620

2010

Volltextzugriff (PDF)

The absence of voiding symptoms in men with a prostate‐specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial

BJU international, 2012-09, Vol.110 (5), p.638-643

2012

Volltextzugriff (PDF)

Is delayed radical prostatectomy in men with low‐risk screen‐detected prostate cancer associated with a higher risk of unfavorable outcomes?

Cancer, 2010-03, Vol.116 (5), p.1281-1290

2010

Volltextzugriff (PDF)

Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC)

BJU international, 2016-11, Vol.118 (5), p.677-680

2016

Volltextzugriff (PDF)

The efficacy of PSA screening: impact of key components in the ERSPC and PLCO trial

Cancer, 2017-12, Vol.124 (6), p.1197-1206

2017

Volltextzugriff (PDF)

The absence of voiding symptoms in men with a PSA ≥ 3.0 ng / mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial

BJU international, 2012-04, Vol.110 (5), p.638-643

2012

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

KollektionSAGE Complete

KollektionWiley Online Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Bju International
(20)
Cancer
(10)
International Journal Of Cancer
(7)
The Prostate
(5)
Int J Cancer
(3)
Medical Journal Of Australia
(3)
Prostate
(2)
Psycho-Oncology
(2)
Journal Of Magnetic Resonance Imaging
(1)
Journal Of Surgical Oncology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

Prostate cancer grading, time to go back to the future

Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma

Prostate Cancer Diffusion‐Weighted Magnetic Resonance Imaging: Does the Choice of Diffusion‐Weighting Level Matter?

Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer

Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial

The dilemmas of prostate cancer screening

Risk of severe late toxicity after radiotherapy following radical prostatectomy – a nationwide study

Lymph swelling after radical prostatectomy and pelvic lymph node dissection

The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials

Oncological and functional outcomes 1 year after radical prostatectomy for very‐low‐risk prostate cancer: results from the prospective LAPPRO trial

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date

Four-hundredfold overestimation of biopsy mortality

Social constraints and psychological well-being after prostate cancer: A follow-up at 12 and 24months after surgery

Four‐hundredfold overestimation of biopsy mortality

Population‐based, nationwide registration of prostatectomies in Sweden

Social constraints and psychological well‐being after prostate cancer: A follow‐up at 12 and 24 months after surgery

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis

The dilemmas of prostate cancer screening

Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen: Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden

The absence of voiding symptoms in men with a prostate‐specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial

Is delayed radical prostatectomy in men with low‐risk screen‐detected prostate cancer associated with a higher risk of unfavorable outcomes?

Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC)

The efficacy of PSA screening: impact of key components in the ERSPC and PLCO trial

The absence of voiding symptoms in men with a PSA ≥ 3.0 ng / mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial

Aktive Filter

Suchergebnisse filtern